These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 28646122)

  • 1. Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
    Liu F; Wang L; Qi H; Wang J; Wang Y; Jiang W; Xu L; Liu N; Zhuang S
    Clin Sci (Lond); 2017 Aug; 131(16):2125-2143. PubMed ID: 28646122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Inhibition of Renal Fibrosis by Nintedanib and Gefitinib in a Murine Model of Obstructive Nephropathy.
    Feng L; Li W; Chao Y; Huan Q; Lu F; Yi W; Jun W; Binbin C; Na L; Shougang Z
    Kidney Dis (Basel); 2021 Jan; 7(1):34-49. PubMed ID: 33614732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
    Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
    J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
    Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
    Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
    Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
    Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway.
    Chen KH; Hsu HH; Yang HY; Tian YC; Ko YC; Yang CW; Hung CC
    Int J Biochem Cell Biol; 2016 May; 74():135-44. PubMed ID: 26948651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for spleen tyrosine kinase in renal fibrosis in the mouse obstructed kidney.
    Ma FY; Blease K; Nikolic-Paterson DJ
    Life Sci; 2016 Feb; 146():192-200. PubMed ID: 26779657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species.
    Samarakoon R; Dobberfuhl AD; Cooley C; Overstreet JM; Patel S; Goldschmeding R; Meldrum KK; Higgins PJ
    Cell Signal; 2013 Nov; 25(11):2198-209. PubMed ID: 23872073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.
    Pang M; Ma L; Gong R; Tolbert E; Mao H; Ponnusamy M; Chin YE; Yan H; Dworkin LD; Zhuang S
    Kidney Int; 2010 Aug; 78(3):257-68. PubMed ID: 20520592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
    Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
    Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis.
    Yan Y; Ma L; Zhou X; Ponnusamy M; Tang J; Zhuang MA; Tolbert E; Bayliss G; Bai J; Zhuang S
    Kidney Int; 2016 Jan; 89(1):68-81. PubMed ID: 26444028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
    Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
    Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
    Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tyrosine kinase receptor signaling attenuates fibrogenesis in an ex vivo model of human renal fibrosis.
    Bigaeva E; Stribos EGD; Mutsaers HAM; Piersma B; Leliveld AM; de Jong IJ; Bank RA; Seelen MA; van Goor H; Wollin L; Olinga P; Boersema M
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F117-F134. PubMed ID: 31736352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amygdalin inhibits renal fibrosis in chronic kidney disease.
    Guo J; Wu W; Sheng M; Yang S; Tan J
    Mol Med Rep; 2013 May; 7(5):1453-7. PubMed ID: 23525378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RIG-I aggravates interstitial fibrosis via c-Myc-mediated fibroblast activation in UUO mice.
    Zhou Z; Ni J; Li J; Huo C; Miao N; Yin F; Cheng Q; Xu D; Xie H; Chen P; Zheng P; Zhang Y; Zhou L; Zhang W; Yu C; Liu J; Lu L
    J Mol Med (Berl); 2020 Apr; 98(4):527-540. PubMed ID: 32036390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomolic Acid Ameliorates Fibroblast Activation and Renal Interstitial Fibrosis through Inhibition of SMAD-STAT Signaling Pathways.
    Park JH; Jang KM; An HJ; Kim JY; Gwon MG; Gu H; Park B; Park KK
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30177595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis.
    Ding H; Jiang L; Xu J; Bai F; Zhou Y; Yuan Q; Luo J; Zen K; Yang J
    Am J Physiol Renal Physiol; 2017 Sep; 313(3):F561-F575. PubMed ID: 28228400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction.
    Baba I; Egi Y; Utsumi H; Kakimoto T; Suzuki K
    Mol Med Rep; 2015 Dec; 12(6):8010-20. PubMed ID: 26498136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.